Related Experiment Video
Updated: Jul 5, 2026
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells
Yanghee Woo1, Kaitlyn J Kelly, Marianne M Stanford
1Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Background:
Viral oncolytic therapy, which seeks to exploit the use of live viruses to treat cancer, has shown promise in the treatment of cancers resistant to conventional anticancer therapies. Among the most difficult to treat cancers is advanced pancreatic adenocarcinoma. Our study investigates the ability of a novel oncolytic agent, myxoma virus, to infect, productively replicate in, and kill human pancreatic cancer cells in vitro.
Methods:
The myxoma virus vMyxgfp was tested against a panel of human pancreatic adenocarcinoma cell lines. Infectivity, viral proliferation, and tumor cell kill were assessed.
Results:
Infection of tumor cells was assessed by expression of the marker gene enhanced green fluorescent protein (e-GFP). vMyxgfp had the ability to infect all pancreatic cancer cell lines tested. Killing of tumor cells varied among the 6 cell lines tested, ranging from >90% cell kill at 7 days for the most sensitive Panc-1 cells, to 39% in the most resistant cell line Capan-2. Sensitivity correlated to replication of virus, and was found to maximally exhibit a four-log increase in foci-forming units for the most sensitive Panc-1 cells within 72 h.
Conclusion:
Our study demonstrates for the first time the ability of the myxoma virus to productively infect, replicate in, and lyse human pancreatic adenocarcinoma cells in vitro. These data encourage further investigation of this virus, which is pathogenic only in rabbits, for treatment of this nearly uniformly fatal cancer.
Insights
Myxoma virus shows promise as an oncolytic therapy for pancreatic cancer. This novel agent effectively infects, replicates in, and kills human pancreatic cancer cells in vitro, offering a new avenue for treating this difficult disease.
Area of Science:
- Oncology
- Virology
- Cancer Therapy
Background:
- Viral oncolytic therapy utilizes live viruses to treat cancer, particularly effective against resistant malignancies.
- Advanced pancreatic adenocarcinoma is a challenging cancer with limited treatment options.
- Myxoma virus is explored as a novel oncolytic agent against pancreatic cancer.
Purpose of the Study:
- To investigate the efficacy of myxoma virus (vMyxgfp) in infecting, replicating within, and inducing cell death in human pancreatic cancer cells in vitro.
- To assess the potential of myxoma virus as a therapeutic agent for pancreatic adenocarcinoma.
Main Methods:
- Human pancreatic adenocarcinoma cell lines were exposed to the myxoma virus vMyxgfp.
- Infectivity was confirmed by enhanced green fluorescent protein (e-GFP) expression.
- Viral proliferation and tumor cell kill rates were quantitatively assessed.
Main Results:
- vMyxgfp successfully infected all tested pancreatic cancer cell lines.
- Tumor cell kill varied significantly, with over 90% cell death in Panc-1 cells and 39% in Capan-2 cells within 7 days.
- Viral replication correlated with sensitivity, showing a four-log increase in foci-forming units in Panc-1 cells within 72 hours.
Conclusions:
- Myxoma virus productively infects, replicates in, and lyses human pancreatic adenocarcinoma cells in vitro.
- These findings support further research into myxoma virus, a rabbit-specific pathogen, for treating pancreatic cancer.
- The study highlights a potential new oncolytic viral therapy for a nearly uniformly fatal cancer.
Related Concept Videos
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...